Partha Pratim Medhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Partha Pratim Medhi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Gautam Sarma
Department of Radiation Oncology, All India Institute of Medical Sciences, Guwahati, Assam, India
4 shared publications - Apurba Kumar Kalita
Radiation Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, IND
3 shared publications - Jyotiman Nath
Department of Radiation Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India
3 shared publications - Mouchumee Bhattacharyya
Radiation Oncology, Dr. Bhubaneswar Borooah Cancer Institute, Guwahati, IND
3 shared publications - Prashasti Sharma
Dr Bhubaneswar Borooah Cancer Institute, Guwahati, India
2 shared publications - Yanpothung Yanthan
Department of Radiation Oncology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
2 shared publications
Latest Publications
- Open Access
- 18 February 2025
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 32 (1) , 22-35
Stereotactic Ablative Radiation Therapy for Metastatic Renal Cell Carcinoma – A Review of Evidence
Because of its remarkable precision in providing targeted radiation, recent evidence supports Stereotactic Ablative Radiation Therapy (SABR) as a promising non-invasive treatment approach for metastatic renal cell carcinoma, minimizing harm to adjacent healthy tissues. With regards to its heterogeneous nature with diverse clinical presentations, rapid progression and metastatic potential, Renal Cell Carcinoma (RCC) is known to make therapy more challenging, and also to reduce the survival rates. Even though Immune Checkpoint Inhibitors (ICIs) remain the gold standard for treating metastatic RCC (mRCC), certain patients with one or a few distant metastases seem to have a longer survival period if the metastases are surgically removed. However, complete responses are not always the case, with radiation being increasingly incorporated as a component of multidisciplinary care. Moreover, studies proving the immunogenic qualities of hypofractionated SABR and the safety and potential of combining SABR with immune-based and surgical therapy for mRCC are becoming more prevalent in the literature. SABR helps induce local inflammation with the tumour, promoting T cell activation and antigen presentation. Multiple retrospective and prospective reports have also demonstrated that SABR assigned to the metastatic locations of mRCC, while using ablative dosages, achieves high local control rates with a good toxicity profile, thus disproving earlier theories of RCC radioresistance. This review outlines the key evidence favouring SABR being administered to metastatic tumours, including the results of recent prospective phase 2 trials in patients with oligometastatic, oligoprogressive, and unselected mRCC. The body of data that has been gathered points to SABR as a promising indicator that is being utilized more and more in the multidisciplinary management of mRCC.
- 18 February 2025
- Published by Vilnius University Press in Acta medica Lituanica
- Vol. 32 (1) , 22-35
Open AccessStereotactic Ablative Radiation Therapy for Metastatic Renal Cell Carcinoma – A Review of Evidence
Because of its remarkable precision in providing targeted radiation, recent evidence supports Stereotactic Ablative Radiation Therapy (SABR) as a promising non-invasive treatment approach for metastatic renal cell carcinoma, minimizing harm to adjacent healthy tissues. With regards to its heterogeneous nature with diverse clinical presentations, rapid progression and metastatic potential, Renal Cell Carcinoma (RCC) is known to make therapy more challenging, and also to reduce the survival rates. Even though Immune Checkpoint Inhibitors (ICIs) remain the gold standard for treating metastatic RCC (mRCC), certain patients with one or a few distant metastases seem to have a longer survival period if the metastases are surgically removed. However, complete responses are not always the case, with radiation being increasingly incorporated as a component of multidisciplinary care. Moreover, studies proving the immunogenic qualities of hypofractionated SABR and the safety and potential of combining SABR with immune-based and surgical therapy for mRCC are becoming more prevalent in the literature. SABR helps induce local inflammation with the tumour, promoting T cell activation and antigen presentation. Multiple retrospective and prospective reports have also demonstrated that SABR assigned to the metastatic locations of mRCC, while using ablative dosages, achieves high local control rates with a good toxicity profile, thus disproving earlier theories of RCC radioresistance. This review outlines the key evidence favouring SABR being administered to metastatic tumours, including the results of recent prospective phase 2 trials in patients with oligometastatic, oligoprogressive, and unselected mRCC. The body of data that has been gathered points to SABR as a promising indicator that is being utilized more and more in the multidisciplinary management of mRCC.
- 31 August 2023
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 76 (1) , 1425-1429
ChatGPT in Head and Neck Oncology-Opportunities and Challenges
Head and neck oncology represents a complex and challenging field, encompassing the diagnosis, treatment and management of various malignancies affecting the intricate anatomical structures of the head and neck region. With advancements in artificial intelligence (AI), chatbot applications have emerged as a promising tool to revolutionize the field of Head and Neck oncology. ChatGPT is a cutting-edge language model developed by OpenAI that can help the oncologist in the clinic in scheduling appointments, establishing a clinical diagnosis, making a treatment plan and follow-up. ChatGPT also plays an essential role in telemedicine consultations, medical documentation, scientific writing and research. ChatGPT carries its inherent drawbacks too. ChatGPT raises significant ethical concerns related to authorship, accountability, transparency, bias, and the potential for misinformation. ChatGPT’s training data is limited to September 2021; thus, regular updates are required to keep pace with the rapidly evolving medical research and advancements. Therefore, a judicial approach to using ChatGPT is of utmost importance. Head and Neck Oncologists can reap the maximum benefit of this technology in terms of patient care, education and research to improve clinical outcomes.
- 31 August 2023
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 76 (1) , 1425-1429
ChatGPT in Head and Neck Oncology-Opportunities and Challenges
Head and neck oncology represents a complex and challenging field, encompassing the diagnosis, treatment and management of various malignancies affecting the intricate anatomical structures of the head and neck region. With advancements in artificial intelligence (AI), chatbot applications have emerged as a promising tool to revolutionize the field of Head and Neck oncology. ChatGPT is a cutting-edge language model developed by OpenAI that can help the oncologist in the clinic in scheduling appointments, establishing a clinical diagnosis, making a treatment plan and follow-up. ChatGPT also plays an essential role in telemedicine consultations, medical documentation, scientific writing and research. ChatGPT carries its inherent drawbacks too. ChatGPT raises significant ethical concerns related to authorship, accountability, transparency, bias, and the potential for misinformation. ChatGPT’s training data is limited to September 2021; thus, regular updates are required to keep pace with the rapidly evolving medical research and advancements. Therefore, a judicial approach to using ChatGPT is of utmost importance. Head and Neck Oncologists can reap the maximum benefit of this technology in terms of patient care, education and research to improve clinical outcomes.
- 1 August 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 9 (Supplement) , 94
Patterns of failure in nasopharyngeal cancer patients of northeastern region of India.
- 1 August 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 9 (Supplement) , 94
Patterns of failure in nasopharyngeal cancer patients of northeastern region of India.
- Open Access
- 1 January 2023
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 11 (3) , 183-190
Factors Associated With Neurocognitive Impairment Following Chemoradiotherapy in Patients With High-Grade Glioma: Results of a Prospective Trial
Sharma P, et al. Brain Tumor Res Treat. 2023 Jul;11(3):183-190. https://doi.org/10.14791/btrt.2023.0004
- 1 January 2023
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 11 (3) , 183-190
Open AccessFactors Associated With Neurocognitive Impairment Following Chemoradiotherapy in Patients With High-Grade Glioma: Results of a Prospective Trial
Sharma P, et al. Brain Tumor Res Treat. 2023 Jul;11(3):183-190. https://doi.org/10.14791/btrt.2023.0004
- 26 November 2020
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 21 (2) , 159-164
Dosimetric comparison of different radiotherapy techniques for the treatment of Retinoblastoma
Aim: This study aims to compare the dosimetric parameters among four different external beam radiotherapy techniques used for the treatment of retinoblastoma.Materials and methods: Computed tomography (CT) sets of five retinoblastoma patients who required radiotherapy to one globe were included. Four different plans were generated for each patient using three dimensional conformal radiotherapy (3DCRT), intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and VMAT using flattening filter free (VMAT-FFF) beam techniques. Plans were compared for target coverage and organs at risk (OARs) sparing.Results: The target coverage of planning target volume (PTV) for all the four modalities were clinically acceptable with a V95 of 95 ± 0%, 97·6 ± 1·87%, 99·3 ± 0·5% and 99·17 ± 0·45% for 3DCRT, IMRT, VMAT and VMAT-FFF respectively. The VMAT and IMRT plans had better target coverage than the 3DCRT plans (p = 0·001 and p = 0·07 respectively). IMRT and VMAT plans were also found superior to 3DCRT plans in terms of OAR sparing like brainstem, optic chiasm, brain (p < 0·05). VMAT delivered significantly lower dose to the brainstem and contralateral optic nerve in comparison to IMRT. Use of VMAT-FFF beams did not show any benefit over VMAT in target coverage and OAR sparing.Conclusion: VMAT should be preferred over 3DCRT and IMRT for treatment of retinoblastoma owing to better target coverage and less dose to most of the OARs. However, IMRT and VMAT should be used with caution because of the increased low dose volumes to the OARs like contralateral lens and eyeball.
- 26 November 2020
- Published by Cambridge University Press (CUP) in Journal of Radiotherapy in Practice
- Vol. 21 (2) , 159-164
Dosimetric comparison of different radiotherapy techniques for the treatment of Retinoblastoma
Aim: This study aims to compare the dosimetric parameters among four different external beam radiotherapy techniques used for the treatment of retinoblastoma.Materials and methods: Computed tomography (CT) sets of five retinoblastoma patients who required radiotherapy to one globe were included. Four different plans were generated for each patient using three dimensional conformal radiotherapy (3DCRT), intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and VMAT using flattening filter free (VMAT-FFF) beam techniques. Plans were compared for target coverage and organs at risk (OARs) sparing.Results: The target coverage of planning target volume (PTV) for all the four modalities were clinically acceptable with a V95 of 95 ± 0%, 97·6 ± 1·87%, 99·3 ± 0·5% and 99·17 ± 0·45% for 3DCRT, IMRT, VMAT and VMAT-FFF respectively. The VMAT and IMRT plans had better target coverage than the 3DCRT plans (p = 0·001 and p = 0·07 respectively). IMRT and VMAT plans were also found superior to 3DCRT plans in terms of OAR sparing like brainstem, optic chiasm, brain (p < 0·05). VMAT delivered significantly lower dose to the brainstem and contralateral optic nerve in comparison to IMRT. Use of VMAT-FFF beams did not show any benefit over VMAT in target coverage and OAR sparing.Conclusion: VMAT should be preferred over 3DCRT and IMRT for treatment of retinoblastoma owing to better target coverage and less dose to most of the OARs. However, IMRT and VMAT should be used with caution because of the increased low dose volumes to the OARs like contralateral lens and eyeball.
- Open Access
- 26 November 2018
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 6 (12) , 3942-3948
Hypofractionated radiotherapy in post mastectomy locally advanced breast cancer: a study from a regional cancer center in North East India
Background: Adjuvant radiotherapy has increased local-regional and overall survival rates in breast cancer. Conventional fractionation delivering 50-60 Gray (Gy) over 5-6weeks is a standard approach. A shorter duration of hypofractionated treatment will be more convenient for patients and treatment providers if found safe and equally effective. Methods: Around 50 high risk breast cancer patients who underwent mastectomy were enrolled and randomized into the study arms- CF (Conventional Fractionation) Arm (50Gy/25 Fr @ 2 Gy/fraction/day 5 days a week over 5weeks) and HF (Hypo-Fractionation) arm (40.05 Gy/15 Fr @ 2.67 Gy/fraction/day 5 days a week over 3weeks). Treatment related acute and late toxicities, loco-regional recurrence; distant metastasis and survival rates were recorded for comparison. Results: Twenty-five patients were enrolled in each arm with baseline characters well matched. At median follow up of 44 months, OS was 80% in HF arm against 64% in CF arm (p-value: 0.292). HF arm also showed better DFS at 4 years of 76% compared to 64% in CF arm (p-value: 0.411). Although the difference was not significant statistically, the Hazard Ratio of 1.543 (95% CI: 0.549-4.339) for DFS and 1.801 (95% CI: 0.603-5.377) for OS indicated trends towards better outcomes in HF arm in terms of disease control and survival. Acute and late toxicities were also lesser in HF arm, though not statistically significant (all p-values >0.05). Conclusions: In post mastectomy setting, HFRT is comparable to CFRT in terms of safety and efficacy, will be more convenient for patients and care givers and hence can be a routine standard practice.
- 26 November 2018
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 6 (12) , 3942-3948
Open AccessHypofractionated radiotherapy in post mastectomy locally advanced breast cancer: a study from a regional cancer center in North East India
Background: Adjuvant radiotherapy has increased local-regional and overall survival rates in breast cancer. Conventional fractionation delivering 50-60 Gray (Gy) over 5-6weeks is a standard approach. A shorter duration of hypofractionated treatment will be more convenient for patients and treatment providers if found safe and equally effective. Methods: Around 50 high risk breast cancer patients who underwent mastectomy were enrolled and randomized into the study arms- CF (Conventional Fractionation) Arm (50Gy/25 Fr @ 2 Gy/fraction/day 5 days a week over 5weeks) and HF (Hypo-Fractionation) arm (40.05 Gy/15 Fr @ 2.67 Gy/fraction/day 5 days a week over 3weeks). Treatment related acute and late toxicities, loco-regional recurrence; distant metastasis and survival rates were recorded for comparison. Results: Twenty-five patients were enrolled in each arm with baseline characters well matched. At median follow up of 44 months, OS was 80% in HF arm against 64% in CF arm (p-value: 0.292). HF arm also showed better DFS at 4 years of 76% compared to 64% in CF arm (p-value: 0.411). Although the difference was not significant statistically, the Hazard Ratio of 1.543 (95% CI: 0.549-4.339) for DFS and 1.801 (95% CI: 0.603-5.377) for OS indicated trends towards better outcomes in HF arm in terms of disease control and survival. Acute and late toxicities were also lesser in HF arm, though not statistically significant (all p-values >0.05). Conclusions: In post mastectomy setting, HFRT is comparable to CFRT in terms of safety and efficacy, will be more convenient for patients and care givers and hence can be a routine standard practice.